ATR and neoplasm: We hypothesized that the combination of oxaliplatin and the ATR inhibitor VE-822 (Vox thereafter) would offer greater tumor control and immunogenicity, favoring the establishment of a potent antitumor immune response and greater sensitivity to anti-PD-1 antibodies.